Adaptive Biotechnologies Corporation (ADPT) Financial Statements
Adaptive Biotechnologies Corporation (ADPT) reported trailing twelve-month revenue of $308.1M (up 50.1% year on year) and net income of -$63.9M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$24.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 4.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.09 | 0.10 | 0.15 | 0.19 | 0.17 | 0.18 | 0.28 | 0.31 | |
| Gross profit | 0.06 | 0.08 | 0.11 | 0.13 | 0.09 | 0.11 | 0.21 | 0.23 | |
| Research & development | 0.07 | 0.12 | 0.14 | 0.14 | 0.12 | 0.10 | 0.09 | 0.09 | |
| Operating income | -0.08 | -0.15 | -0.21 | -0.20 | -0.23 | -0.16 | -0.06 | -0.04 | |
| Pre-tax income | -0.07 | -0.15 | -0.21 | -0.20 | -0.23 | -0.16 | -0.06 | -0.06 | |
| Income tax | — | — | — | — | — | — | 0.00 | — | |
| Net income | -0.07 | -0.15 | -0.21 | -0.20 | -0.23 | -0.16 | -0.06 | -0.06 | |
| Diluted EPS ($) | -1.01 | -1.11 | -1.48 | -1.40 | -1.56 | -1.08 | -0.39 | -0.41 | |
| Diluted shares (bn) | — | — | — | 0.143 | 0.144 | 0.147 | 0.152 | — |
USD billions · SEC XBRL
Adaptive Biotechnologies Corporation — questions
- What is Adaptive Biotechnologies Corporation's revenue?
- $308.1M over the twelve months to 2026-06-30, up 50.1% year on year, from its 10-Q and 10-K filings.
- What is Adaptive Biotechnologies Corporation's net income?
- -$63.9M over the twelve months to 2026-06-30.
- What is Adaptive Biotechnologies Corporation's free cash flow?
- -$24.0M over the twelve months to 2026-06-30.
- What are Adaptive Biotechnologies Corporation's diluted earnings per share?
- $-0.41 over the twelve months to 2026-06-30.
Every figure on this page comes from Adaptive Biotechnologies Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.